Illumina Files New Patent Infringement Suit
News May 19, 2015
Illumina has announced that the company has filed a new patent infringement suit against Ariosa Diagnostics, Inc. and its parent company, Roche Molecular Systems, Inc. Illumina is seeking all available remedies.
The new suit, filed in the U.S. District Court for the Northern District of California, is based on Ariosa’s infringement of U.S. Patent No. 7,955,794 (the ‘794 patent), entitled “Multiplex Nucleic Acid Reactions.” The suit is focused on Ariosa’s Microarray-based version of its Harmony™ Prenatal Test.
Illumina and its wholly owned subsidiary, Verinata Health, Inc., previously filed suits in the U.S. District Court for the Northern District of California against Ariosa accusing its Sequencing-based version of the Harmony Prenatal Test of infringing the ‘794 patent and U.S. Patent No. 8,296,076 and U.S. Patent No. 8,318,430. Those previous suits remain pending.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.